It is an exciting time for oncology drug development, characterized by rapid innovation and significant advancements in personalized medicine, and the landscape is witnessing a surge in clinical trials exploring novel mechanisms of action, biomarkers and combination therapies to overcome resistance and enhance efficacy.
What treatment modalities are healthcare providers (HCPs) most excited about? What groundbreaking research is piquing their interest? Are antibody-drug conjugates (ADCs) and theranostics — potentially transformative therapies getting the spotlight of late — living up to their hype?
These questions and more will be answered through a survey of HCPs attending the European Society for Medical Oncology (ESMO) annual meeting — one of the premier events in the oncology community, bringing together thousands of oncologists, researchers and healthcare professionals from around the world to share the latest scientific developments, research findings and clinical advancements in cancer treatment.
Join an engaging webinar that will unveil insights from oncologists surveyed at the ESMO 2024 conference. The expert speakers will identify and explore the data that oncologists consider most impactful from the conference and provide a closer look at the transformative potential of ADCs and theranostics. They will also examine the oncology drug development landscape, highlighting the surge in innovative trials and the strategic shifts in treatment approaches.
Register for this webinar to understand what treatment modalities and research are capturing the attention of oncologists and healthcare professionals in oncology drug development.
Speakers
Dr. Wouter Bartholomeus, MD, Executive Medical Director Oncology & Hematology, Syneos Health
Dr. Wouter Bartholomeus is a medical doctor with over 10 years of experience in clinical research, primarily within the oncology and hematology therapeutic areas. His expertise includes immuno-oncology, targeted therapy, biosimilars and early-phase studies.
With extensive experience in combining both medical and operational aspects of international oncology clinical trials and language skills, Dr. Bartholomeus is well-versed in the management of global clinical studies from early phase through Phase IV and experienced in protocol development to ensure protocol adherence, subject safety and data integrity.
Message Presenter
Dr. Patrick Kelly, MD, Vice President, Medical Management, Oncology & Hematology, Syneos Health
Dr. Patrick Kelly is a renowned and board-certified pediatric hematologist/oncologist with an impressive background in both the clinical setting and the pharmaceutical industry.
His extensive professional journey includes nearly 15 years of academic and clinical leadership in hematology/oncology, followed by more than 15 years of global industry experience in early- and late-stage drug development with targeted anti-cancer agents.
Notably, he has served key roles at Wyeth, Pfizer, Infinity and Forma, where he played integral parts in advancing therapies and shaping the landscape of medical innovation. He has successfully led clinical activities for biologics, ADCs and small molecular therapeutics, resulting in multiple IND submissions and FDA approvals, thus contributing significantly to the advancement of treatments for various diseases.
Message Presenter
Dr. Prateet Minhas, MD, Managing Director, Consulting, Syneos Health
Dr. Prateet Minhas is a Managing Director at Syneos Health, helping companies develop and commercialize therapies at optimal price and access.
As a trained Physician and globally recognized leader in life science consulting, Dr. Minhas brings over 15 years of experience in treating patients and supporting biopharmaceutical clients to secure market access to therapies at the optimal price.
He has successfully led/delivered over 250 market access and commercial strategy projects with a particular focus on Europe, APAC and LATAM. In addition, Dr. Minhas has supported various clients in HTA negotiations with payers in Brazil, China, Denmark, Finland, Italy, Norway, Spain and Sweden.
His hands-on experience in negotiating with payers and authorities has enabled him to provide actionable recommendations to clients and support them in the complete journey from strategy development to actual reimbursement and access for therapies.
Dr. Minhas earned an MBA with merit from Imperial College London. He is also a trained Physician with an MBBS from Maulana Azad Medical College in New Delhi, India.
Message PresenterWho Should Attend?
This webinar will appeal to:
- Oncologists and healthcare providers involved in cancer care
- Clinical researchers and scientists in the field of oncology
- Pharmaceutical and biotech professionals
- Medical students and trainees interested in oncology
- Healthcare policymakers and stakeholders
What You Will Learn
In this webinar, attendees will:
- Understand how new data unveiled at ESMO 2024 may impact the future of cancer treatment
- Review the status of current ADCs in oncology and how to get the next generation of ADCs into first-in-human trials
- Get the latest information on the constantly evolving field of theranostics and its promise to significantly improve treatment outcomes
Xtalks Partner
Syneos Health®
Syneos Health® is a leading fully integrated biopharmaceutical solutions organization built to accelerate customer success. They translate unique clinical, medical affairs and commercial insights into outcomes to address modern market realities. Together they share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. They support a diverse, equitable and inclusive culture.
To learn more about how we are shortening the distance from lab to life®, visit syneoshealth.com or subscribe to our podcast.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account